...
首页> 外文期刊>Annals of surgical oncology >Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy
【24h】

Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy

机译:肿瘤减少乳房成形术和放射疗法治疗的乳腺癌患者的局部复发模式

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The purpose of this study was to describe the incidence and location of ipsilateral breast tumor recurrence (IBTR) among breast cancer patients treated with oncoplastic reduction mammoplasty (ORM) and radiotherapy (RT). Methods: The medical records of 86 consecutive women with ductal carcinoma in situ (DCIS) (n = 11) or invasive carcinoma of the breast (n = 75) treated with ORM at Emory University between January 1994 and December 2010 were reviewed. Results: Following ORM, prolonged wound healing or surgical complications led to delay of adjuvant chemotherapy or RT in 11 patients. Surgical clips were found outside the primary tumor breast quadrant in 43 % of the patients with available RT planning CT images. When the clips were found outside the primary tumor quadrant, the RT boost was more frequently delivered outside versus inside the primary tumor quadrant (67 vs. 33 %, p < 0.001). After a median follow-up period of 4.5 years (range 0.1-17.9), 6 patients developed an IBTR and only 1 IBTR occurred outside the primary tumor quadrant. The 5-year ipsilateral breast tumor control rates were 91 % (95 % CI 0.82-0.99) and 93 % (95 % CI 0.90-0.97) for patients with DCIS and invasive carcinoma, respectively. Conclusions: The use of ORM yields acceptable rates of IBTR. ORM may displace breast tissue and surgical clips to breast quadrants outside of the original tumor location, but the majority of IBTRs still occur in the original tumor quadrant. This area remains at highest risk of in-breast recurrence in women treated with ORM irrespective of surgical clip location.
机译:背景:这项研究的目的是描述在接受肿瘤成形术复位乳腺成形术(ORM)和放射疗法(RT)治疗的乳腺癌患者中,同侧乳腺肿瘤复发(IBTR)的发生率和位置。方法:回顾性分析了1994年1月至2010年12月间在Emory大学接受ORM治疗的86例连续女性原位导管癌(DCIS)(n = 11)或乳腺浸润癌(n = 75)的病历。结果:ORM后,长期的伤口愈合或手术并发症导致11例患者的辅助化疗或RT延迟。在具有可用的RT计划CT图像的患者中,有43%的患者在原发肿瘤乳腺象限之外发现了手术夹。当在原发性肿瘤象限外发现夹子时,RT增强在原发性肿瘤象限内比在内部更频繁地递送(67%vs. 33%,p <0.001)。在中位随访期4.5年(范围0.1-17.9)后,有6例患者发生了IBTR,而在原发肿瘤象限之外仅发生了1 IBTR。 DCIS和浸润性癌患者的5年同侧乳腺肿瘤控制率分别为91%(95%CI 0.82-0.99)和93%(95%CI 0.90-0.97)。结论:使用ORM可以产生可接受的IBTR率。 ORM可能会将乳腺组织和手术夹子移位到原始肿瘤位置之外的乳腺象限,但是大多数IBTR仍发生在原始肿瘤象限中。无论手术夹的位置如何,在接受ORM治疗的女性中,该区域的乳房内复发风险最高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号